Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China

Kunpeng Li,Jingyu Jin,Jinshui Yang,Yan Li,Wei Zhao,Gui Luo,Jian Zhu,Jianglin Zhang,Feng Huang

Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China

2018

Kunpeng Li
Jingyu Jin
Jinshui Yang
Yan Li
Wei Zhao
Gui Luo
Jian Zhu
Jianglin Zhang
Feng Huang

Introduction To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW).

Keywords:

Internal medicine
Biosimilar
Axial spondyloarthritis
Discontinuation
Etanercept
Intensive care medicine
Cardiology
Medicine
Adalimumab
Clinical endpoint
once weekly
Gastroenterology
every other week
median time

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations